Editas Medicine Inc. held its 2025 Annual Meeting of Stockholders on May 29, 2025. During the meeting, stockholders elected Jessica Hopfield, Ph.D., and David Scadden, M.D., as Class III directors. Additionally, stockholders approved an amendment to the Restated Certificate of Incorporation to increase the number of authorized shares of capital stock and common stock. An amendment and restatement of the 2015 Stock Incentive Plan was also approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.